Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
Recent: |
|
Past: |
|
The medicine, called Leqembi, slowed decline by 27 percent over 18 months compared with placebo, a study showed. But side effects and cost are fueling controversy. → Read More
A drug called Leqembi, which modestly slows progression of the disease, is expected soon to receive full approval from federal regulators. → Read More
Controversies surrounding the drug — involving safety concerns, the drug’s modest efficacy and its high cost — continue to swirl. → Read More
The drug, donanemab, is the latest treatment to target amyloid beta, a protein that builds up in the brain and is a signature characteristic of Alzheimer’s. → Read More
For years, doctors and patients thought there was little to do when dementia was diagnosed, even at an early stage. Now, potentially sweeping changes loom. → Read More
The proposed change is designed to reduce the complexity of the vaccine regimen for the public, doctors and manufacturers. → Read More
The Food and Drug Administration said it needed safety data on more patients, the company said. → Read More
The drug, lecanemab, removes a sticky protein from the brain called amyloid beta, which is thought to play a key role in the memory-robbing illness. → Read More
For the first time, simple blood tests are emerging as potentially crucial tools to help physicians pinpoint Alzheimer's. → Read More
It is a discouraging development that underscores the challenges of developing treatments for the memory-robbing disease. → Read More
Adults can receive the Novavax booster six months after completing their primary series of any coronavirus vaccine, including Moderna and Pfizer shots. → Read More
The drug, Relyvrio, is only the third ALS treatment cleared by the Food and Drug Administration in almost three decades. → Read More
The newly approved therapy, called AMX0035, is designed to slow the disease by protecting nerve cells in the brain and spinal cord destroyed by ALS. → Read More
Makers of the drug have already applied to the Food and Drug Administration for accelerated approval for lecanemab, based on earlier-stage data. → Read More
The vote increases the likelihood that the Food and Drug Administration will clear the first drug for the disease in five years. → Read More
The therapy is the latest to raise questions about how the FDA assesses drugs for devastating diseases, such as ALS and Alzheimer's. → Read More
The shots are expected to be available right after Labor Day. → Read More
Millions of machines used to treat the sleep condition have been recalled. → Read More
Food and Drug Administration Commissioner Robert M. Califf said in a statement that “the agency has confronted a series of challenges." → Read More
The request hands regulators a major reproductive health issue weeks after the Supreme Court decision striking down the constitutional right to abortion. → Read More